The 2026 review does not change adult acne care yet because topical clascoterone helps modestly and lacks direct tests against standard hormonal care. Topical hormonal therapy here means clascoterone 1% cream, a skin-applied drug that blocks androgen signals in skin. Persistent acne means breakouts that continue through adulthood without long clear breaks. For those readers, the review adds a local option without replacing proven backbones.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why is clascoterone called topical hormonal therapy?
- How much improvement did trials show?
- Why do guidelines still favor older treatments first?
- What can adults with persistent acne do now?
Why is clascoterone called topical hormonal therapy?
MDPI Pharmaceuticals explains in the 2026 Pharmaceuticals review that clascoterone 1% cream blocks cutaneous androgen receptors. Less receptor signaling means less drive for clogged pores and inflamed pimples. The effect stays largely in skin rather than the whole body.
The same review notes rapid metabolism to inactive cortexolone after skin action. Fast breakdown limits whole-body exposure. That profile allows use in males and females, unlike systemic spironolactone.
How much improvement did trials show?
The MDPI review of Hebert trials reports IGA success, meaning clear or almost clear, in 19.9% versus 7.7% on vehicle at 12 weeks. Total lesion counts fell 37.8% versus 25.1% in the same period. Both measures cover inflammatory and non-inflammatory lesions.
The gap is real but small. Most users did not reach clear or almost clear. Expect partial help, not full control for stubborn adult disease.
Why do guidelines still favor older treatments first?
The American Academy of Dermatology guidance summarized by The Hospitalist strongly recommends benzoyl peroxide, topical retinoids and antibiotics in the AAD guideline summary. The same summary gives only a conditional recommendation to topical clascoterone. Strong support reflects larger and more consistent benefit across patients.
Researchers in the Journal of the European Academy of Dermatology found 50.8% of adult women had acne most days without clear periods. The Journal team also reported frequent scarring, detailed in the adult-women acne study. Long-lasting disease needs treatments with the strongest record first.
What can adults with persistent acne do now?
Healio Dermatology notes the pivotal data come from 12-week vehicle-controlled trials in Healio Dermatology's trial report. There was no head-to-head test against systemic hormonal therapies. There were also no long-term outcomes specific to adult persistent acne.
Keep the proven backbone and treat clascoterone as a possible add-on. Talk with a dermatologist about fit for your pattern. Bring a list of past retinoids, benzoyl peroxide use, and hormonal treatments tried to that visit.
- Keep a retinoid plus benzoyl peroxide base if tolerated.
- Ask whether adding clascoterone suits male or female adult acne.
- Discuss proven systemic hormonal options if acne in women resists topicals.
You Might Also Like
- Limited Topical Spironolactone Evidence in the 2026 Review: Who Was Studied and Who Was Not for Adults With Persistent Acne
- Adult Female Acne Antiandrogen Treatments in a 2026 Review: Who Was Studied and Who Was Not for Adults With Persistent Acne
- Spironolactone, Metformin, and Bicalutamide for Acne in a 2026 Review: Who Was Studied and Who Was Not for Adults With Persistent Acne